ELISA News and Research

RSS

OMG to conduct Terminology Services Information Day to explore terminology services

OMG(TM) today announced that a special event, Terminology Services Information Day, will be co-located with the OMG Technical Meeting in Long Beach, CA USA on December 8, 2009. For more information and to register for this special event, please visit http://www.omg.org/terminology-services-day.

31 Oct 2009

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Kidney transplant consent forms are often written at a level that makes it difficult for many kidney patients to fully understand them, according to a paper being presented at the American Society of Nephrology's annual meeting in San Diego, CA. The study findings indicate that consent forms are written on average at a 12th-grade reading level, but to ensure all patients fully comprehend treatment options should be prepared at a 5th - 8th grade reading level.

30 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Victims of mobbing show behavioral and social inhibition; less skilled to face environmental challenges

A study by Naples investigators published in the current issue of Psychotherapy and Psychosomatics reports on what happens in the axis which controls the secretion of cortisol in victims of mobbing.

27 Oct 2009

eBioscience acquires privately held immunoassay technology pioneer Bender MedSystems

eBioscience Corporation today announced that it has acquired privately held immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA® and FlowCytomix(TM) brands that target the life sciences and diagnostics markets.

27 Oct 2009

New Category I CPT code for AspirinWorks Test Kit

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today that a new Category I Current Procedural Terminology (CPT) code has been published by the American Medical Association (AMA) for the AspirinWorks Test Kit.

23 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

Canary Foundation to implement biosensor technologies for early cancer detection

Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.

12 Oct 2009

Diamedix files a 510(k) premarket submission with the FDA for its Mago4S assay system

IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration (“FDA”) for its next -generation fully automated Enzyme-linked Immunosorbent Assay (“ELISA”) system for autoimmune and infectious disease testing, named the Mago®4S.

1 Oct 2009

Athera Biotechnologies and ALPCO sign distribution agreement

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing high quality research immunoassays, announced today that they have signed a distribution agreement.

25 Sep 2009

ColoMarker assay achieves 100 percent detection rate for colon cancers

Marking a major milestone in the early detection and management of colon cancer, EDP Biotech Corporation (EDP), a developer of immunodiagnostic tests for humans and animals, announced today that its ColoMarker assay achieved 100 percent detection rate for colon cancers presented at stages I through III in pre-clinical trials.

17 Sep 2009

Urine LAM-ELISA's sensitivity of 50.7% in identifying TB disappoints

Urine LAM-ELISA does not appear to be useful as an independent diagnostic test for pulmonary tuberculosis (TB). A trial of the new diagnostic, described in the open access journal BMC Infectious Diseases found that it was only capable of identifying 50.7% of TB cases.

28 Aug 2009

Fatty liver associated with metabolic problems

New findings from nutrition researchers at Washington University School of Medicine in St. Louis suggest that it's not whether body fat is stored in the belly that affects metabolic risk factors for diabetes, high blood triglycerides and cardiovascular disease, but whether it collects in the liver.

25 Aug 2009

Genway Clinical Laboratory offers ELISA-based test that detects tumor markers in blood serum

GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum.

24 Aug 2009

Curemark closes $6.5 million Series A round of funding

Curemark, a privately held drug research and development company, announced today that it has closed a $6.5M Series A round of funding.

10 Aug 2009

Measuring fragile X mental retardation

Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.

24 Jun 2009

Axela launches nine plate based tumor marker assays

Available in high performance ELISA format they have been designed for stand alone use or to simplify the transition to automated dotLab assays.

9 Apr 2009

Having synchronous cancers means better survival outcome

New research published in this month's edition of Obstetrics & Gynecology (Vol. 113, Issue 4), by a team of investigators from The Cancer Institute of New Jersey (CINJ) shows better survival outcomes for women who have cancer of the ovaries and endometrial lining of the uterus at the same time (synchronous) than those who only have one tumor in the ovaries.

6 Apr 2009

FDA looks at nanotechnology for the detection of anthrax

The U.S. Food and Drug Administration has completed a "proof-of-concept" study of a test that quickly and accurately detects the presence of even the smallest amount of the deadly anthrax toxin.

17 Mar 2009